As LogiPharma kicks off this week we hosted a dinner with attendees from various leading pharmaceutical and life sciences organisations.
The event provided an opportunity for networking and knowledge sharing, with discussion focused on supply chain and pharma strategies, topics dominating the industry, and key opportunities ahead of the conference.
Here are some of our key takeaways from our conversations at the event:
- AI moving from experimentation to impact: the conversation highlighted a shift away from AI as a theoretical capability towards practical, value driven use cases. Participants discussed where AI is already delivering tangible benefits across planning, forecasting and decision making, while also recognising that trust, data quality and user adoption remain critical factors
- Resilience and responsible sourcing are now inseparable: against a backdrop of ongoing geopolitical instability and conflict in parts of the world, including the Middle East, supply chain resilience was repeatedly linked to how organisations adapt their sourcing decisions under pressure. Beyond pure risk mitigation, there was strong emphasis on transparency, supplier accountability, and the need to embed ethical and sustainability considerations directly into network design and sourcing strategies, ensuring supply chains remain robust, flexible and responsible in an increasingly uncertain environment
- The strategic value of meeting suppliers face to face: despite advances in digital collaboration, attendees agreed that investing time to meet suppliers in person remains essential. These interactions help build trust, improve alignment and strengthen long term partnerships
- Flexible network design as a buffer against disruption: recent and ongoing disruptions reinforced the importance of adaptable network design. Rather than optimising for a single “steady state”, organisations are increasingly building flexibility into their logistics and manufacturing footprints to respond more effectively to volatility
- Transformation requires focus and prioritisation: a recurring discussion point was the need to be selective when driving transformation. With new systems, processes and operating models all competing for attention, participants emphasised that organisations cannot transform everything at once, success depends on clear priorities and phased delivery
- M&A brings operational and cultural complexity: whether being acquired or growing through acquisition, M&A was highlighted as a major turning point. Beyond scale and scope, leaders discussed the implications for culture, operating models, and network optimisation
We were delighted to connect with peers from across the industry and look forward to continuing the conversation at LogiPharma this week. If you’re attending the conference, stop by stand 55 and say hi to our team.
Share:
